Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
INAB Stock Forecast 2026-2027
$2.59
Current Price
$25.28M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to INAB Price Targets
+1,347.9%
To High Target of $37.50
+131.7%
To Median Target of $6.00
+15.8%
To Low Target of $3.00
INAB Price Momentum
+18.8%
1 Week Change
+114.0%
1 Month Change
-70.8%
1 Year Change
+10.7%
Year-to-Date Change
-79.3%
From 52W High of $12.54
+121.4%
From 52W Low of $1.17
๐ TOP ANALYST CALLS
Did INAB Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if IN8bio is one of their latest high-conviction picks.
Latest INAB Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, INAB has a bullish consensus with a median price target of $6.00 (ranging from $3.00 to $37.50). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $2.59, the median forecast implies a 131.7% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Kalpit Patel at B. Riley Securities, suggesting a 15.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INAB Analyst Ratings
4
Buy
0
Hold
0
Sell
INAB Price Target Range
Low
$3.00
Average
$6.00
High
$37.50
Current: $2.59
Latest INAB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INAB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 14, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $6.00 |
| Feb 12, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $8.00 |
| Feb 11, 2025 | Jones Trading | Soumit Roy | Buy | Upgrade | $1.20 |
| Nov 26, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $8.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $8.00 |
| Aug 12, 2024 | Jones Trading | Soumit Roy | Hold | Downgrade | $N/A |
| Jun 14, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $12.50 |
| Jun 14, 2024 | Jones Trading | Soumit Roy | Buy | Maintains | $6.50 |
| Jun 4, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $12.50 |
| May 13, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $12.50 |
| Apr 10, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Mar 18, 2024 | Laidlaw & Co. | Yale Jen | Buy | Initiates | $7.50 |
| Mar 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Mar 13, 2024 | JonesTrading | Soumit Roy | Buy | Initiates | $5.00 |
| Nov 13, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Jun 5, 2023 | EF Hutton | Tony Butler | Buy | Reiterates | $8.00 |
| May 16, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Apr 26, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Apr 24, 2023 | Mizuho | Mara Goldstein | Buy | Reiterates | $12.00 |
IN8bio Inc. (INAB) Competitors
The following stocks are similar to IN8bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IN8bio Inc. (INAB) Financial Data
IN8bio Inc. has a market capitalization of $25.28M with a P/E ratio of -0.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -189.7%.
Valuation Metrics
Market Cap
$25.28M
Enterprise Value
$3.02M
P/E Ratio
-0.2x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+89.0%
Current Ratio
6.9x
Debt/Equity
22.4x
ROE
-189.7%
ROA
-80.4%
๐ก SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
IN8bio Inc. (INAB) Business Model
About IN8bio Inc.
What They Do
Develops innovative T cell therapies for cancer.
Business Model
The company operates as a clinical-stage biopharmaceutical entity, focusing on the discovery and commercialization of gamma-delta T cell therapies. It generates revenue through the development of its proprietary DeltExโข platform, which supports various therapeutic approaches, including allogeneic and genetically modified T cells, targeting specific cancer types in clinical trials.
Additional Information
IN8bio's lead candidates, INB-400 and INB-200, are in trials for glioblastoma, while INB-100 targets hematologic malignancies in bone marrow transplant patients. The company is also advancing multiple preclinical programs aimed at treating solid and hematological tumors, underscoring its commitment to innovative cancer therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
17
CEO
Mr. Tai-Wei Ho
Country
United States
IPO Year
2021
Website
in8bio.comIN8bio Inc. (INAB) Latest News & Analysis
Latest News
Quick Summary
IN8bio, Inc. (Nasdaq: INAB) reported positive updated clinical data from its INB-200 and INB-400 trials for glioblastoma, showing improved progression-free survival compared to standard treatments.
Why It Matters
The positive clinical trial results for IN8bio's therapies indicate potential advancements in treating glioblastoma, which could enhance market value and attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
IN8bio secured $40.2 million in a private placement to advance INB-619, extending its cash runway into H1 2027. The financing was led by Coastlands Capital and includes institutional investors.
Why It Matters
The $40.2 million funding extends IN8bio's cash runway, enhancing its ability to advance cancer therapies and potentially increasing shareholder value as development progresses.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
IN8bio presented preclinical data on its INB-619 T cell engager, showing strong potency and minimal adverse effects. They expanded the Phase 1 trial for INB-100 and plan to present GBM data in 2025.
Why It Matters
IN8bio's positive data on INB-619 suggests strong competitive positioning in the T cell therapy market, potentially attracting investment and increasing stock value due to improved safety and efficacy.
Source: GlobeNewsWire
Market Sentiment:
Neutral
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
2 months ago
Quick Summary
IN8bio, Inc. has added The Ohio State University as a clinical site for its Phase 1 trial of INB-100, a gamma-delta T cell therapy for leukemia, enhancing enrollment efforts.
Why It Matters
The addition of The Ohio State University as a clinical site enhances IN8bio's credibility and could accelerate trial progress, potentially leading to quicker market entry and positive investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
2 months ago
Quick Summary
INB-619 shows comparable efficacy to FDA-approved T cell engagers with fewer side effects, representing a targeted approach for safer B cell depletion and efficient ฮณฮด T cell expansion.
Why It Matters
INB-619's efficacy and safety profile may disrupt the TCE market, attracting investor interest due to potential market share gains and advancements in cancer treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
IN8bio (INAB) Q2 Loss Narrows 77%
5 months ago
Quick Summary
IN8bio (INAB) reported a 77% reduction in losses for Q2.
Why It Matters
The 77% reduction in Q2 losses for IN8bio indicates improved financial health and operational efficiency, potentially boosting investor confidence and stock performance.
Source: The Motley Fool
Market Sentiment:
Neutral
Frequently Asked Questions About INAB Stock
What is IN8bio Inc.'s (INAB) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, IN8bio Inc. (INAB) has a median price target of $6.00. The highest price target is $37.50 and the lowest is $3.00.
Is INAB stock a good investment in 2026?
According to current analyst ratings, INAB has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.59. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INAB stock?
Wall Street analysts predict INAB stock could reach $6.00 in the next 12 months. This represents a 131.7% increase from the current price of $2.59. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is IN8bio Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical entity, focusing on the discovery and commercialization of gamma-delta T cell therapies. It generates revenue through the development of its proprietary DeltExโข platform, which supports various therapeutic approaches, including allogeneic and genetically modified T cells, targeting specific cancer types in clinical trials.
What is the highest forecasted price for INAB IN8bio Inc.?
The highest price target for INAB is $37.50 from at , which represents a 1,347.9% increase from the current price of $2.59.
What is the lowest forecasted price for INAB IN8bio Inc.?
The lowest price target for INAB is $3.00 from Kalpit Patel at B. Riley Securities, which represents a 15.8% increase from the current price of $2.59.
What is the overall INAB consensus from analysts for IN8bio Inc.?
The overall analyst consensus for INAB is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are INAB stock price projections?
Stock price projections, including those for IN8bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 8:19 AM UTC